SAREE AONGSOMWANG

Foundation for Consumers, Thailand

CCPN Founded 1982, as a coordinating body on health

Registered as a Foundation for Consumers, 1996Non government, non profit ‘no advertising, no bias’Publishes Smart buyer Magazine and Online ++Center for Consumers’ interestCampaigns for Policy &Capacity building for

consumer organizations24 staff , 4 paid volunteer & 20 Volunteers Lawyer

IN 1994

(Complaint one time is better than

complain 1,000 times)

Currently FFC has become the

leading non-govermental and non-

profit organization in Thailand to work

directly with consumers and

consumer protection policy advocacy.

And we will continue to stand side by

side with all Thai consumers.

http://www.consumerthai.org/smbuyer/index.php?option=com_content&task=blogsection&id=10&Itemid=47

CHAPTER [ ]

INTELLECTUAL PROPERTY RIGHTS

1. Each Party shall, at a minimum, give effect to this.

International Agreements 2. 1,Further to Article the Parties affirm their existing rigggg ggg ggggggggggg gggg ggggggg gg gggg ggggg gggg ggg ggggg gggggggggg.

3. Each Party shall ratify or accede to the following gggggggggg gg ggg gggg gg ggggg gggg ggggg g gggg gggggggggg: () Patent Cooperation Treaty (1970), as amended i

1979n ; (b) Paris Convention for the Protection of Industrial

Property (1967); (c) Berne Convention for the Protection of Literary

and Artistic Works (1971); (d) Convention Relating to the Distribution of Progr

- amme Carrying Signals Transmitted by Satellite (1974);

(e) Protocol Relating to the Madrid Agreement Con cerning the International Registration of Marks (1

989);

(f) Budapest Treaty on the International Recognition o f the Deposit of Microorganisms for the Purposes of P

atent Procedure (1977), as amended in 1980; (g) International Convention for the Protection of New

Varieties of Plants (1991) (UPOV onvention); (h) Singapore Treaty on the Law of Trademarks (2006)

; (i) WIPO Copyright Treaty (1996); and (j) WIPO Performances and Phonograms Treaty (1996).

4. Each Party shall notify the WTO of its acceptan ce of the Protocol amending the TRIPS

AgreementdoneatGenevaonDecember6, 2005. 5. Each Par t y shal l make al l r easonabl e eff or t

s r at i f y or accede t o t he f ol l owi ng agreementsby t he dat e of ent r y i nt o f or ce of t he Agr eeme

: (a) Patent Law Treaty (2000); and (b) Hague Agreement Concerning the Internationa

l Registration of Industrial Designs (1999).

Trademarks 1. No Party may require, as a condition of registration,

that a sign be visually perceptible, nor may a Party d eny registration of a trademark solely on the ground

s that the sign of which it is composed is a sound or ascent.

2 . Each Party shall provide that trademarks shall incl udecertificationmar ks. Each Par t y shal l al so pr ovi de t hat geogr aphicali ndi cat i ons ar e el i gi bl e f or pr ot ect i on as t r ademarks.

1. Each Party shall make patents available for a g ggggggg gg gggggggg gg ggg gggggg gg ggggggggggg gggggggg ggg,, , ttheinventionisnew, i nvol ves an i nvent i ve st ep, and i s capab gggggggggg gggggggggggg gg ggggggggg ggg ggggggg gggg., ggggg ggggggg ggggg gg ggggggggg ggg : anynewforms, uses, orme

thods of using a known product; and a new for m, use, or met hod of usi ng a known pr oduct may satgggg ggg gggggggg ggg ggggggggggggg , even ig gggg ggggggggg gggg ggg gggggg gg ggg gggggggg entof t he known effi cacy of t hat pr oduct .

2. Each Party shall make patents available for inventi ons for the following:

(a) plants and animals, and (b) diagnostic, therapeutic, and surgical methods for t

he treatment of humans or animals. 3. EachPar t y may onl y excl ude f r ompat ent abi l i t y i nve

ntions, the prevention within its territory of the com mercial exploitation of which is necessary to protect

ordre public or morality, including to protect human, animal, or plant life or health or to avoid serious prej

udice to the environment, provided that such exclusi on is not made merely because the exploitation is pr

ohibited by law.

4. EachPartymaypr ovi de l i mi t ed except i ons t o t he excl usi ve r ights conferred by a patent, provided that such exce

ptions do not unreasonably conflict with a normal ex ploitation of the patent and do not unreasonably prej

udice the legitimate interests of the patent owner, ta kingaccount of t he l egi t i mat e i nt er est s of t hi r d parties. 5. [ Placeholder for “Bolar” provision] 6. [ Placeholder for provisions concerning patent term restoration/adjustment ]

9. Each Par t y shal l pr ovi de pat ent appl i cant s wi t h at l east one oppor t uni t y t o make amendment s , c

orrections, and observations in connection with their applications. EachPar t y shal l per mi t appl i cant s t o make amendme ntst o t hei r pat ent cl ai ms pr i or t o r ecei pt of a fi r stpat ent offi ce act i on or communi cat i on on t he merits.

10. Each Party shall provide that a disclosure of a cl aimed invention shall be considered to be sufficientl

y clear and complete if it provides information that al lows the invention to be made and used by a person

skilledi n t he ar t , without undue experimentation , asof t h efi l i ng dat e.

Pharmaceutical Products 2 . [ Placeholder for provisions related to data prot

ection for pharmaceutical products] 3. [ Placeholder for provisions related to patent lin

kage] General Provisions

4. [ Placeholder for provisions related to patent te rm/data protection relationship]

5. [ Placeholder for definitions of “new pharmaceuti cal product” and “new agricultural product”]

1. Each Party shall provide that final judicial decisiggg ggg ggg ggggggggggg ggggggg gg ggggggg gggggggg

ion pertaining to the enforcement of intellectual pggggggg gggggg ggggg gg gg g gggggg ggg ggggg ggggg ggg gggggggg gggggggg gg gggg ggg ggg ggggggggg gg g

he legal basis on which the decisions and rulings are based. Each Party shall also provide that such

decisions and rulings shall be published1 6 or, wherepublicationisnot r act i cabl e, ot her wi se made avai l abl e t o thepublic, i n i t s nat i onal l anguage i n such a manner as toenabl e gover nment s and r i ght hol der s t o beco meacquai nt ed wi t h t hem.

National Budget on Health National Budget on Health CareCare

Access to medicineAccess to medicine

to compensate the delays by drug registration or in patent granting process

Filing date+

0

Expired date++

20 years++

Patent term

Drug registration (marketing)+

(Jiraporn, 2005)

APPLY for PATENTYEAR0 NO PATENT

YEARDRUG REGISTRATION1

2 DRUG APPROVED to be in MARKETDATA

EXCLUSIVITY

5-10 Yrs.

20PATENT LIFE 20 Yrs. DATA

EXCLUSIVITY

5-10 Yrs.

DRUG REGISTRATION1 8 19DRUG APPROVED to be in MARKET

(Jiraporn, 2005)

Rovira modelMarkov model

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

ข ยายอาย�จากล่�าช้ า 2 ปี� 27,883 24,002 55,236 91,249 255,324

ข ยายอาย�จากผู�กโยง 2 ปี� 27,883 24,002 55,236 91,249 255,324

ข ยายอาย�จากล่�าช้ า 5 ปี� 27,883 46,494 136,922 221,502 619,773

ข ยายอาย�จากผู�กโยง 5 ปี� 27,883 46,494 136,922 221,502 619,773

ผู�กข าดข อมู�ล่ยา 5 ปี� 81,356 97,442 125,888 156,390 233,447

ข ยายอาย�จากล่�าช้ า 10 ปี� 27,883 83,960 205,307 423,180 1,180,399

ผู�กข าดข อมู�ล่ยา 10 ปี� 99,163 206,688 269,238 341,888 525,049

next 5 years (2556) next 10 years (2561) next 15 years (2566) next 20 years (2571) next 30 years (2581)

extension 2 years

extension 5 years

extension 10 years

DE 5 yrs.

DE 10 yrs.

Comparison of Local Production and Import Medicinefrom 1990 and 2010

9,176.52

48,823.13

4,319.26

107,394.25дѥіяј ѧшѕѥ ј Җѥьэѥъ

дѥіьѼѥѝѤѷкѕѥ ј Җѥьэѥъ

ъѨѷєѥ: ѝѼѥьѤдѕѥ

юѨ

% )% )

% )

% )

Comparison of Population in 1990 and 2010

ё ћ ё ћ

Population Million

Million % )

ъѨѷєѥ: ѝѼѥьѤдкѥьѝщѧшѧѰўҕкнѥшѧюѨ